{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Solu-Medrol+250+mg", "query": { "intervention": "Solu-Medrol 250 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Solu-Medrol+250+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T01:37:11.627Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01105650", "title": "Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer", "Breast Cancer" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Natural killer cells", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 13, "start_date": "2010-07", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-09-25T01:37:11.627Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01105650" }, { "nct_id": "NCT00576069", "title": "Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Asthma" ], "interventions": [ { "name": "budesonide/formoterol", "type": "DRUG" }, { "name": "fluticasone/salmeterol", "type": "DRUG" }, { "name": "mometasone/formoterol", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gelb, Arthur F., M.D.", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "10 Years to 95 Years" }, "enrollment_count": 60, "start_date": "2007-10-25", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-09-25T01:37:11.627Z", "location_count": 1, "location_summary": "Lakewood, California", "locations": [ { "city": "Lakewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00576069" }, { "nct_id": "NCT00771875", "title": "Randomized Trial for Mixed Acute Rejection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Rejection" ], "interventions": [ { "name": "Rabbit Antithymocyte Globulin (RATG)", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Antihistamine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2008-09", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2016-01-27", "last_synced_at": "2026-09-25T01:37:11.627Z", "location_count": 2, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00771875" }, { "nct_id": "NCT00481832", "title": "Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Antithymocyte globulin", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Autologous hematopoietic stem cell transplantation (auto-HSCT)", "type": "PROCEDURE" }, { "name": "Allogeneic hematopoietic stem cell transplantation (allo-HSCT)", "type": "PROCEDURE" }, { "name": "Total lymphoid irradiation", "type": "PROCEDURE" }, { "name": "CD34+ Cells", "type": "DRUG" }, { "name": "Solu-Medrol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 50, "start_date": "2007-01", "completion_date": "2017-03-30", "has_results": true, "last_update_posted_date": "2018-02-14", "last_synced_at": "2026-09-25T01:37:11.627Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00481832" }, { "nct_id": "NCT00482053", "title": "Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, B-cell", "Lymphoma, Non-Hodgkin", "Diffuse Large B-cell Lymphoma (DLBCL)", "Malignant Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Autologous hematopoietic stem cell transplantation (auto-HSCT)", "type": "PROCEDURE" }, { "name": "Allogeneic hematopoietic stem cell transplantation (allo-HSCT)", "type": "PROCEDURE" }, { "name": "Total lymphoid irradiation (TLI)", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Anti-thymocyte globulin (ATG)", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 3, "start_date": "2006-10", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2018-05-14", "last_synced_at": "2026-09-25T01:37:11.627Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00482053" }, { "nct_id": "NCT04233164", "title": "Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Systemic Lupus Erythematous (SLE)" ], "interventions": [ { "name": "Solu-Medrol 1mg/kg", "type": "DRUG" }, { "name": "Solu-Medrol 250 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 47, "start_date": "2020-03-04", "completion_date": "2022-05-03", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-09-25T01:37:11.627Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04233164" }, { "nct_id": "NCT02798523", "title": "Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Normal Physiology" ], "interventions": [ { "name": "Methylprednisolone sodium succinate(Solu-Medrol)", "type": "DRUG" }, { "name": "Topical methylprednisolone (Advantan emulsion 0 /1%)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 33, "start_date": "2017-01-24", "completion_date": "2022-11-14", "has_results": true, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-09-25T01:37:11.627Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02798523" }, { "nct_id": "NCT04066114", "title": "Treg Modulation With CD28 and IL-6 Receptor Antagonists", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Living-Donor Kidney Transplant", "Kidney Transplant Recipients" ], "interventions": [ { "name": "lulizumab pegol", "type": "BIOLOGICAL" }, { "name": "antithymocyte globulin (rabbit)", "type": "BIOLOGICAL" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "tocilizumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "belatacept", "type": "BIOLOGICAL" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "mycophenolic acid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2019-12-11", "completion_date": "2023-09-14", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-09-25T01:37:11.627Z", "location_count": 7, "location_summary": "Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04066114" }, { "nct_id": "NCT00732498", "title": "Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "In-Zevalin", "type": "DRUG" }, { "name": "Y-Zevalin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2006-05-15", "completion_date": "2018-10-15", "has_results": true, "last_update_posted_date": "2019-09-04", "last_synced_at": "2026-09-25T01:37:11.627Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00732498" }, { "nct_id": "NCT01856257", "title": "Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Renal Allograft Candidate", "Kidney Transplantation" ], "interventions": [ { "name": "Anti-thymocyte Globulin (Rabbit)", "type": "BIOLOGICAL" }, { "name": "belatacept", "type": "BIOLOGICAL" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "basiliximab", "type": "BIOLOGICAL" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 71, "start_date": "2013-07", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-09-25T01:37:11.627Z", "location_count": 3, "location_summary": "Birmingham, Alabama • San Francisco, California • Atlanta, Georgia", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01856257" } ] }